In focus · trending topic

EASL 2017

3 stories · following the connections

Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)

By Nasdaq OMXApr 12, 2017, 8:08 PM UTC

Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)

By Nasdaq OMXApr 12, 2017, 8:08 PM UTC

Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)

By Nasdaq OMXApr 12, 2017, 8:08 PM UTC